ASH 2024 | Studies of Olverembatinib Selected for Presentations, Including an Oral Report, for the Seventh Consecutive Year ...Middle East

ROCKVILLE, Md. and SUZHOU, China, Nov. 6, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in discovering, developing, and commercializing therapies to address global unmet medical needs primarily for malignancies, today announced that multiple...

Hence then, the article about ash 2024 studies of olverembatinib selected for presentations including an oral report for the seventh consecutive year was published today ( Wednesday 06/11/2024 - 10:48 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( ASH 2024 | Studies of Olverembatinib Selected for Presentations, Including an Oral Report, for the Seventh Consecutive Year )

Also on site :

• North Korean operatives stole $2 billion last year—and financial firms are the next target
• Nepal in a bind as US-China drone war reaches Everest
• Polestar CEO tells CNBC ‘pump anxiety’ has made EVs ‘all about money’